Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
I'm LongbridgeAI, I can summarize articles.Needham analyst Gil Blum reiterates a Buy rating on CRISPR Therapeutics with an $82 price target. He cites the company's broad pipeline, strategic priorities, and upcoming 2026 data catalysts as key drivers. Blum highlights growth potential for Casgevy in broader populations and autoimmune indications, alongside upside in in vivo gene editing and allogeneic cell therapy programs.
Gil Blum, an analyst from Needham, maintained the Buy rating on Crispr Therapeutics AG. The associated price target remains the same with $82.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Gil Blum has given his Buy rating due to a combination of factors, including the breadth of Crispr Therapeutics’ pipeline and the company’s clear strategic priorities for the coming years. Management highlighted several upcoming data catalysts in the second half of 2026, which Blum views as important value inflection points that can further validate the platform and support long-term growth.
He also emphasizes the life cycle opportunities for Casgevy, particularly its potential to reach broader patient populations and expand into additional indications. Furthermore, he sees meaningful upside in the company’s in vivo gene editing and allogeneic cell therapy programs, especially in autoimmune diseases, which together support maintaining his $82 price target and Buy rating.
Blum covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Lyell Immunopharma, and Cartesian Therapeutics. According to TipRanks, Blum has an average return of 14.1% and a 44.60% success rate on recommended stocks.